

Modulation of gene expression by vitamin B₆

T. Oka

*Department of Veterinary Physiology, Faculty of Agriculture, Kagoshima University,
1-21-24 Korimoto, Kagoshima 890-0065, Japan*

The physiologically active form of vitamin B₆, pyridoxal 5'-phosphate (PLP), is known to function as a cofactor in many enzymic reactions in amino acid metabolism. Recent studies have shown that, apart from its role as a coenzyme, PLP acts as a modulator of steroid hormone receptor-mediated gene expression. Specifically, elevation of intracellular PLP leads to a decreased transcriptional response to glucocorticoid hormones, progesterone, androgens, and oestrogens. For example, the induction of cytosolic aspartate aminotransferase (cAspAT) in rat liver by hydrocortisone is suppressed by the administration of pyridoxine. The suppression of the cAspAT induction by pyridoxine is caused by a decrease in the expression of the cAspAT gene, which is brought about by inactivation of the binding activity of the glucocorticoid receptor to the glucocorticoid-responsive element in the regulatory region of the cAspAT gene. Vitamin B₆ has recently been found to modulate gene expression not only for steroid hormone-responsive or PLP-dependent enzymes but also for steroid- and PLP-unrelated proteins such as serum albumin. Albumin gene expression was found to be modulated by vitamin B₆ through a novel mechanism that involves inactivation of tissue-specific transcription factors, such as HNF-1 or C/EBP, by direct interaction with PLP in a similar manner to glucocorticoid receptor. Enhancement of albumin gene expression in the liver by an increased supply of amino acids can be explained by elevated binding of HNF-1 and C/EBP to their DNA-binding sites which, in turn, is caused by a decrease in the intracellular level of PLP by the increased amino acid supply. These findings that vitamin B₆ acts as a physiological modulator of gene expression add a new dimension to the hitherto recognized function of vitamin B₆ as a cofactor of enzyme action.

**Vitamin B₆: Gene expression: Transcription factors: Steroid hormones:
Albumin: Cancer**

Abbreviations cAspAT, cytosolic aspartate aminotransferase; GRE, glucocorticoid-responsive elements; PLP, pyridoxal 5'-phosphate; PMP, pyridoxamine 5'-phosphate; PN, pyridoxine.

Corresponding author: Professor T. Oka, fax +81 99 285 8714, email oka@vet.agri.kagoshima-u.ac.jp

Introduction

Vitamin B₆ is a water-soluble vitamin essential for normal growth, development and metabolism (Tryfiates, 1980; Merrill & Henderson, 1987). The physiologically active form of the vitamin, pyridoxal 5'-phosphate (PLP), is derived from inactive dietary precursors and functions as a cofactor in numerous enzyme reactions of amino acid metabolism (Merrill *et al.* 1984).

Apart from its role as a coenzyme, PLP is known to be an inhibitor of many enzymes that have binding sites for phosphate-containing substrates or effectors, including RNA polymerase (Venegas *et al.* 1973; Martial *et al.* 1975), reverse transcriptase (Basu *et al.* 1989), and DNA polymerase (Modak, 1976; Diffley, 1988). In all these cases, PLP is far more effective than other vitamins. It typically interacts with proteins by forming a Schiff base between its aldehyde group and primary amino groups, most commonly the ε-amino groups of lysine residues (Fisher *et al.* 1958).

The present review describes the recent emergence of vitamin B₆ as a modulator of gene expression through a novel mechanism that involves inactivation of tissue-specific transcription factors, in addition to its role in modulating gene expression in response to steroid hormones.

Vitamin B₆ and steroid hormone action

It is well known that vitamin B₆ affects enzyme induction by steroid hormones. Nishigori *et al.* (1978) first showed that treatment of partially purified progesterone receptor preparations with PLP could inhibit the binding of progesterone receptor to ATP-sepharose. At about the same time, Cake *et al.* (1978) showed that PLP inhibits binding of rat-liver glucocorticoid receptor to DNA-cellulose. Since then, several laboratories have established a correlation between vitamin B₆ and steroid hormone action. DiSorbo & Litwack (1981) reported that incubation of rat hepatoma in a pyridoxine (PN)-free medium resulted in a decrease in the intracellular level of PLP and significant enhancement of the induction of tyrosine aminotransferase. Similarly, the work of Majumder *et al.* (1983) showed that increased concentrations of vitamin B₆ inhibited glucocorticoid-induced casein mRNA accumulation in the mouse mammary gland. Allgood *et al.* (1990) demonstrated that vitamin B₆ modulates transcriptional activation by the human glucocorticoid receptor in HeLa cells. Allgood & Cidlowski (1992) subsequently showed that the modulatory effect of vitamin B₆ on transcription activation is not limited to the glucocorticoid receptor but extends to multiple members of the steroid hormone receptor superfamily. They further reported that modulation of vitamin B₆ of glucocorticoid receptor-mediated gene expression requires transcription factor NF1 in addition to the glucocorticoid receptor (Allgood *et al.* 1993). These results indicate that increased intracellular PLP leads to decreased transcriptional responses to glucocorticoids, progesterone, androgens and oestrogens. Conversely, cells in a vitamin B₆-deficient state exhibit enhanced responsiveness to steroid hormones. These studies have been reviewed by Tully *et al.* (1994).

Vitamin B₆ and gene expression of liver enzymes

The evidence for an interaction between PLP and steroid hormone receptors, described in the preceding section, has been mainly obtained with the use of subcellular extracts or cultured cells. However, an indication of possible interaction between vitamin B₆ and steroid hormones in the whole animal has existed for some time (Bender, 1987, 1994). For example, cytosolic aspartate aminotransferase (cAspAT) in rat liver is a PLP-dependent enzyme and the activity of

the enzyme is induced by the administration of glucocorticoid hormones. Kondo & Okada (1985) found that the induction of the enzyme in the liver of adrenalectomized vitamin B₆-deficient rats by hydrocortisone was suppressed by the administration of PN.

We recently found that the level of cAspAT mRNA in the liver of vitamin B₆-deficient rats was several-fold higher than that of the control rats (Oka *et al.* 1995a). The administration of hydrocortisone induced expression of the hepatic cAspAT mRNA and the induction was suppressed by the simultaneous administration of PN. Since the 5' regulatory region of the rat cAspAT gene contains several sequences showing homology to glucocorticoid-responsive elements (GRE), we synthesized an oligonucleotide probe of GRE sequence and assayed the binding activity of nuclear extract to the oligonucleotide by gel mobility shift analysis. We found that the binding activity of nuclear extract prepared from the liver of vitamin B₆-deficient rats was far greater than that of the control rats, indicating that the DNA-binding activity of the glucocorticoid receptor was enhanced by vitamin B₆ deficiency. We further found that preincubation of the nuclear extract with PLP brought about a rapid and extensive decrease in the binding of the extract to GRE. Analogues of PLP, such as pyridoxamine 5'-phosphate (PMP), pyridoxal, pyridoxamine or PN, did not show an inhibitory effect. These observations suggest that PLP modulates cAspAT gene expression by inactivating the binding of glucocorticoid receptor to GRE.

Glycogen phosphorylase is another PLP-dependent enzyme, which catalyzes the first step in the intracellular degradation of glycogen. We observed that the level of phosphorylase mRNA was also increased several-fold in the liver of vitamin B₆-deficient rats, compared with vitamin B₆-supplemented controls (Oka *et al.* 1994). Presumably, vitamin B₆ acts in the same way as in the case of cAspAT. However, the effect of vitamin B₆ deficiency on phosphorylase was tissue-specific; the level of phosphorylase mRNA in the skeletal muscle of vitamin B₆-deficient rats was reduced, to 40 % of that in the control rats, rather than increased as in the liver.

In the course of the study on the effect of vitamin B₆ deficiency on the expression of liver enzymes, we made an unexpected observation. cAspAT and phosphorylase, two enzymes so far described, are PLP-dependent enzymes and one may rationalize the involvement of vitamin B₆ in the control of expression of their genes. However, examination of additional liver enzymes revealed that gene expression of several enzymes, not related to PLP or steroid hormones, were also influenced by vitamin B₆ nutritional status. Thus, mRNA levels of apolipoprotein A-1, phenylalanine hydroxylase, glyceraldehyde-3-phosphate dehydrogenase and β -actin were elevated in the liver of vitamin B₆-deficient rats (Oka *et al.* 1993). Additionally, the activities of RNA polymerase I and II were found to be increased in vitamin B₆ deficiency. The latter finding indicates that the earlier demonstration *in vitro* of PLP as an inhibitor of RNA polymerase (Venegas *et al.* 1973; Martial *et al.* 1975) may have some physiological significance. The enhanced expression of several vitamin B₆-independent enzymes in the liver of vitamin B₆-deficient rats might be explained, at least in part, by the elevation of RNA polymerase activity.

Vitamin B₆ and expression of the albumin gene

Serum albumin represents the most abundant protein synthesized in and secreted by the liver. Among the vitamin B₆-independent enzymes and proteins whose gene expression is enhanced by vitamin B₆ deficiency, we noted that the level of albumin mRNA was increased 7-fold over the control level (Oka *et al.* 1995b). The magnitude of the increase in albumin mRNA was far greater than can be explained in terms of increased RNA polymerase activity.

Studies of transcription of the rat albumin gene have shown that the 170-nucleotide region immediately upstream of the transcription initiation site is sufficient for tissue-specific expression of the gene. Several *cis*-acting elements have been identified in this region that interact with various transcription factors including HNF-1, C/EBP, CTF/NF1 and NFY (Cereghini *et al.* 1987; Marie *et al.* 1989) (Fig. 1). However, there is a hierarchy of importance of the various factors for albumin gene expression; the HNF-1 (–45 to –62) and C/EBP-binding sites (–136 to –160) activate transcription more strongly than the other sites (Marie *et al.* 1989). We synthesized two oligonucleotides, which interact with HNF-1 and C/EBP respectively, and determined the binding activities of liver nuclear extracts to each of these oligonucleotides by mobility-shift analysis. We found that the activity of the extract prepared from liver of vitamin B₆-deficient rats was greater than that of the controls. As the concentrations of C/EBP in nuclear extracts from control and vitamin-deficient rats, estimated by Western-blot analysis, were essentially the same, the lower binding activity of the extract from control liver is probably due to inactivation of tissue-specific factors by PLP and/or its analogues. We therefore examined the effect of PLP and other vitamin B₆ vitamers on the binding activity of nuclear extract *in vitro* and found that only PLP effectively inhibited the binding. These observations are analogous to the inactivation of glucocorticoid receptor by PLP, described above, and indicate that vitamin B₆ modulates albumin gene expression through a novel mechanism that involves inactivation of tissue-specific transcription factors by direct interaction with PLP (Fig. 2).

In order to elucidate the molecular mechanism whereby DNA-binding activity of tissue-specific transcription factors is inhibited by PLP, we recently produced recombinant HNF-1 in *Escherichia coli* and determined the site of attachment of PLP *in vitro*. Determination of amino acid sequence of PLP-containing peptide revealed that PLP was bound to lysine 197 of HNF-1 molecule (T Oka, unpublished results; Fig. 3). Inasmuch as lysine 197 lies in the homeodomain of HNF-1, PLP binding to this lysine residue would render the HNF-1 molecule less accessible to the HNF-1 binding site of the albumin gene.

Expression of the albumin gene and amino acid and protein nutrition

As noted above, serum albumin represents the most abundant protein synthesized in the liver. It has long been recognized that the protein-nutritional status of animals affects the synthesis of albumin. Chiku *et al.* (1993) showed that depletion of amino acid supply to rats during total parenteral nutrition did not alter the fractional synthesis rate of liver domestic proteins but decreased the synthesis rate of serum proteins, particularly albumin. However, little is known about the molecular mechanism whereby the levels of amino acid supply to animals differentially affects the synthetic rates of domestic proteins and serum proteins in the liver.




Fig. 1. Schematic representation of the transcriptional factors interacting with the regulatory region of the albumin gene. The HNF-1(–45 to –62) and C/EBP-binding sites (–136 to –160) activate transcription more strongly than the other sites (Marie *et al.* 1989).




Fig. 2. Diagram of binding of transcription factors and RNA polymerase to a regulatory region and a TATA site of DNA respectively. DNA-binding activities are inhibited by interaction of pyridoxal 5'-phosphate (PLP) to transcription factors and RNA polymerase.




Fig. 3. Binding of pyridoxal 5'-phosphate (PLP) to transcription factor, HNF-1. PLP-binding to lysine-197 is in the homeodomain of HNF-1.

In our recent study (Oka *et al.* 1997), rats were nourished by infusion of total parenteral nutrition solutions containing 0 or 33 g amino acids/kg for 7 d. The level of albumin mRNA in the liver of amino acid-infused rats was found to be several-fold higher than that in the liver of amino acid-depleted rats. Since the expression of the albumin gene is regulated by tissue-specific transcription factors, HNF-1 and C/EBP, we determined the binding activities of nuclear extracts to the HNF-1- and C/EBP-binding sites by mobility-shift analysis and found that the activity of the extract prepared from livers of amino acid-infused rats was greater than that of amino acid-depleted rats. In view of the involvement of vitamin B₆ in the modulation of albumin gene expression, we determined the intracellular concentrations of vitamin B₆ derivatives and found that the PLP concentration in the liver of amino acid-infused rats was decreased

to almost a half that of amino acid-depleted rats while PMP concentration was increased proportionally. These observations suggest that a decrease in intracellular PLP, in turn, relieves inactivation of tissue-specific transcription factors for the expression of the albumin gene.

The question as to how amino-acid infusion decreases hepatic PLP concentration may be raised. Amino acids, transported into hepatic cells, will undergo transamination reactions catalyzed by aminotransferases. Since PLP is the coenzyme of all the aminotransferase and enzyme-bound PLP is converted to PMP during transamination, the continuous influx of amino acids may decrease PLP concentration and elevate PMP concentration in the steady state (Fig. 4).

Vitamin B₆ and platelet aggregation

PLP has been shown to inhibit *in vitro* platelet aggregation induced by ADP, collagen, thrombin, adrenaline and arachidonic acid (Kloczowia & Freinberg, 1980; Chang & Mak, 1999). It is well known that platelet aggregation is mediated by a common mechanism that involves the binding of fibrinogen or other adhesive proteins to GPIIb/IIIa complexes of platelets (Nurden & Phillip, 1990). GPIIb/IIIa is the major receptor protein on platelet membranes and is responsible for aggregation. The final step of all platelet-aggregating agents is the functional expression of GPIIb/IIIa on the platelet surface, which ligates fibrinogen to link platelets together as part of the aggregation process (Verstraete & Zoldhelyi, 1995).

Glycoprotein Iib (GPIIb) is the α -subunit of the platelet membrane receptor GPIIb/IIIa, which plays a major role in platelet aggregation. Chang *et al.* (1999) analysed the molecular mechanism of vitamin B₆ on anti-aggregation of platelet by analysing the expression of GPIIb promoter-driven reporter gene. The GPIIb promoter region was amplified by polymerase chain reaction, cloned into pBLCAT3 to drive the CAT reporter gene and transfected into human erythroleukaemia cells. Transient expression of the GPIIb promoter was determined after transfected cells were treated with 1 μ M PN, pyridoxal, PLP or 4-deoxypyridoxine. GPIIb promoter activity was down-regulated to 54, 35 and 63 % in the presence of PN, pyridoxal and PLP respectively as compared with an untreated control. However, no adverse effect on GPIIb promoter was detected by 4-deoxypyridoxine, which is an antagonist of vitamin B₆. The down-regulatory effect of vitamin B₆ on GPIIb promoter activity may lead to a reduction of GPIIb protein expression and thus be detrimental to platelet aggregation.

These observations are analogous to the inactivation of HNF1 and C/EBP by PLP, described above, and indicate that vitamin B₆ modulates GPIIb gene expression through a novel




Fig. 4. Proposed regulatory mechanism of albumin gene expression by amino acids. PLP, pyridoxal 5'-phosphate; PMP, pyridoxamine 5'-phosphate.

mechanism that involves inactivation of tissue-specific transcription factors by direct interaction with PLP.

Vitamin B₆ and gene expression of c-fos in nerve cells

Alterations in neuronal proto-oncogene expression have been reported in conditions such as brain injury, receptive stimulation, or seizures induced by metrazol or kindling (Dragunow & Robertson, 1987, 1988). For example, c-fos expression is increased after seizures induced by metrazol (Morgan *et al.* 1987).

It is known that vitamin B₆ is involved in nerve cell function and vitamin B₆ antagonists cause seizures in various mammals (Makino & Matsuda, 1960). Mizuno *et al.* (1989) examined the effect of vitamin B₆ antagonists on the expression of the c-fos gene in the brain. They observed that only 4-deoxypyridoxine among various vitamin B₆ antagonists was effective in increasing the level of c-fos mRNA and c-fos protein in nerve cells; c-fos mRNA increased slightly at 10 min after deoxypyridoxine administration, was maximal at 60 min and then returned to the basal level at 120 min. The clinical manifestation of seizures corresponded well with the increase in c-fos mRNA level in brain around 60 min after deoxypyridoxine administration. Treated mice were observed to behave normally at 120 min when c-fos mRNA had returned to the basal level. Administration of deoxypyridoxine causes a vitamin B₆-deficient state in mice; these observations also indicate that vitamin B₆ modulates c-fos gene expression through a novel mechanism.

Vitamin B₆ and cancer

The level of plasma vitamin B₆ in cancer patients is lower than that of healthy subjects (Potera *et al.* 1977; Chrisley & Hendricks, 1986), suggesting that administration of vitamin B₆ to cancer patients may be therapeutically useful. The growth of rat hepatoma Fu5-5 cells and human malignant melanoma NEL cells was inhibited on culture in a medium supplemented with 5 mM and 0.5 mM PN respectively (DiSorbo & Litwack, 1982; DiSorbo & Nathanson, 1983).

We recently found that the growth of human hepatoma HepG2 cells was completely inhibited in medium supplemented with PN in the millimolar range. The growth inhibition of HepG2 cells was accompanied by a marked inhibition of gene expression, protein synthesis and secretion of serum proteins, particularly albumin. Pyridoxal was as effective as PN, but pyridoxamine showed no inhibitory action (Molina *et al.* 1997). The electron-microscopic examination of PN-treated HepG2 cells revealed a smoothing of nuclear membrane, a decrease in the number of nucleoli, and the appearance of aggregated heterochromatin structures. These morphological features were compatible with depressed transcriptional activity in the PN-treated cells. We also found that the growth of MH-134 hepatoma cells, transplanted into C3H/He mice, was significantly retarded by the administration of large doses of PN. The expression of oncogenes, such as c-fos and c-myc, was considerably reduced in the tumours, probably by a similar mechanism to the inhibition of albumin gene expression by vitamin B₆ (T Oka, unpublished results).

The anti-tumour effect of vitamin B₆ is not limited to liver cancer alone; recent studies have shown that dietary supplementation of vitamin B₆ markedly suppresses azoxymethane-induced colon carcinogenesis in mice (Komatsu *et al.* 2001). Application of the supraphysiological doses of vitamin B₆ as an antineoplastic therapy is a promising area for future research.

Conclusions

Vitamin B₆ has long been recognized as a cofactor for many enzymes, especially those involved in amino acid metabolism. Apart from its role as coenzyme, recent studies are unveiling a new role of vitamin B₆ as a modulator of gene expression. Vitamin B₆ modulates gene expression by interaction with not only steroid hormone receptors but also with many tissue-specific transcription factors such as HNF-1 and C/EBP.

References

- Allgood VE & Cidlowski JA (1992) Vitamin B₆ modulates transcriptional activation by multiple members of the steroid hormone receptor superfamily. *Journal of Biological Chemistry* **267**, 3819–3824.
- Allgood VE, Oakley RH & Cidlowski JA (1993) Modulation by vitamin B₆ of glucocorticoid receptor-mediated gene expression requires transcription factors in addition to the glucocorticoid receptor. *Journal of Biological Chemistry* **268**, 20870–20876.
- Allgood VE, Powell-Oliver FE & Cidlowski JA (1990) Vitamin B₆ influences glucocorticoid receptor-dependent gene expression. *Journal of Biological Chemistry* **265**, 12424–12433.
- Basu A, Tirumalai RS & Modak MJ (1989) Substrate binding in human immunodeficiency virus reverse transcriptase. *Journal of Biological Chemistry* **264**, 8746–8752.
- Bender DA (1987) Oestrogens and vitamin B₆ – actions and interactions. *World Review of Nutrition and Dietetics* **51**, 140–189.
- Bender DA (1994) Novel functions of vitamin B₆. *Proceedings of the Nutrition Society* **53**, 625–630.
- Cake MH, DiSorbo DM & Litwack G (1978) Effect of pyridoxal phosphate on the DNA binding site of activated hepatic glucocorticoid receptor. *Journal of Biological Chemistry* **253**, 4886–4891.
- Cereghini S, Raymondjean M, Carranca AG, Herbomel P & Yaniv M (1987) Factors involved in control of tissue-specific expression of albumin gene. *Cell* **50**, 627–638.
- Chang SJ, Chuang HJ & Chen HH (1999) Vitamin B₆ down-regulates the expression of human GPIIb gene. *Journal of Nutritional Science and Vitaminology* **45**, 471–479.
- Chang SJ & Mak OT (1999) The optimal levels of vitamin B₆ in platelet function and blood coagulation of rabbits. *Nutrition Research* **19**, 65–73.
- Chiku K, Mochida H, Yamamoto M & Natori Y (1993) Amino acids suppress intracellular protein degradation in rat liver during parenteral nutrition. *Journal of Nutrition* **123**, 1771–1776.
- Chrisley BM & Hendricks TS (1986) Vitamin B₆ status of a group of cancer patients. *Nutrition Research* **6**, 1023–1029.
- Diffley JFX (1988) Affinity labeling the DNA polymerase a complex. 1. Pyridoxal 5'-phosphate inhibition of DNA polymerase a complex from *Drosophila melanogaster* embryos. *Journal of Biological Chemistry* **263**, 14669–14677.
- DiSorbo DM & Litwack G (1981) Changes in the intracellular levels of pyridoxal 5'-phosphate affect the induction of tyrosine aminotransferase by glucocorticoid. *Biochemical and Biophysical Research Communications* **99**, 1203–1208.
- DiSorbo DM & Litwack G (1982) Vitamin B₆ kills hepatoma cells in culture. *Nutrition and Cancer* **3**, 216–222.
- DiSorbo DM & Nathanson L (1983) High-dose pyridoxal supplemented culture medium inhibits the growth of a human malignant myeloma cell line. *Nutrition and Cancer* **5**, 10–15.
- Dragunow M & Robertson HA (1987) Kindling stimulation induced c-fos protein(s) in granule cells of the rat dentate gyrus. *Nature (London)* **329**, 441–442.
- Dragunow M & Robertson HA (1988) Brain injury induced c-fos protein(s) in nerve and glia-like cells in adult mammalian brain. *Brain Research* **455**, 295–299.
- Fisher EH, Kent AB, Snyder ER & Krebs EG (1958) The reaction of sodium borohydride with muscle phosphorylase. *Journal of the American Chemical Society* **80**, 2906–2907.
- Kloczowia KM & Freinberg H (1980) Pyridoxal phosphate inhibition on platelet function. *American Journal of Physiology* **238**, H54–H60.
- Komatsu S, Watanabe H, Oka T, Tsuge H, Nii H & Kato N (2001) Supplemental vitamin B₆ suppresses azoxymethane-induced colon tumorigenesis in mice by reducing cell proliferation. *Journal of Nutrition* **131**, 2204–2207.
- Kondo T & Okada M (1985) Effect of pyridoxine administration on the induction of cytosolic aspartate aminotransferase in the liver of rats treated with hydrocortisone. *Journal of Nutritional Science and Vitaminology* **31**, 509–517.
- Majumder PK, Joshi JB & Banerjee MR (1983) Correlation between nuclear glucocorticoid receptor levels and casein gene expression in murine mammary gland *in vitro*. *Journal of Biological Chemistry* **258**, 6793–6798.
- Makino K & Matsuda M (1960) Vitamin B₆ enzymes and convulsion. *Shinkei Kenkyu no Shimpo (Japanese)* **4**, 72–76.
- Marie P, Wuarin J & Shibler U (1989) The role of *cis*-acting promoter elements in tissue-specific albumin gene expression in rat liver. *Science* **244**, 343–346.
- Martial L, Zardivar J, Bull P, Venegas A & Valenzuela P (1975) Inactivation of rat liver RNA polymerase I and II and

- yeast RNA polymerase I by pyridoxal 5'-phosphate. Evidence for the participation of lysyl residue at the active site. *Biochemistry* **14**, 4907–4911.
- Merrill AH & Henderson JM (1987) Disease associated with deficiencies in vitamin B₆ metabolism or utilization. *Annual Review of Nutrition* **7**, 137–156.
- Merrill AH, Henderson JM, Wang E, McDonald BW & Millikan WJ (1984) Metabolism of vitamin B₆ by human liver. *Journal of Nutrition* **114**, 1664–1674.
- Mizuno AM, Mizobuchi T, Ishibashi Y & Matsuda M (1989) c-Fos mRNA induction under vitamin B6 antagonist-induced seizure. *Neuroscience Letters* **98**, 272–275.
- Modak MJ (1976) Observation on the pyridoxal 5'-phosphate inhibition of DNA polymerases. *Biochemistry* **15**, 3620–3626.
- Molina A, Oka T, Munoz S, Chikamori-Aoyama M, Kuwahata M & Natori Y (1997) Vitamin B₆ suppresses growth and expression of albumin gene in a human hepatoma cell line HepG2. *Nutrition and Cancer* **28**, 206–211.
- Morgan JI, Cohen DR, Hempstead JL & Curran T (1987) Mapping pattern of c-fos expression in the central nervous system after seizure. *Science* **237**, 192–197.
- Nishigori H, Moudgli VK & Toft D (1978) Inactivation of avian progesterone receptor binding to ATP-sepharose by pyridoxal 5'-phosphate. *Biochemical and Biophysical Research Communications* **80**, 112–118.
- Nurden AT & Phillip DR (1990) Platelet membrane glycoproteins: functions in cellular interactions. *Annual Review of Cell Biology* **6**, 329–357.
- Oka T, Komori N, Kuwahata M, Hiroi Y, Shimoda T, Okada M & Natori Y (1995a) Pyridoxal 5'-phosphate modulates expression of cytosolic aspartate aminotransferase gene by inactivation of glucocorticoid receptor. *Journal of Nutritional Science and Vitaminology* **41**, 363–375.
- Oka T, Komori N, Kuwahata M, Okada M & Natori Y (1995b) Vitamin B₆ modulates expression of albumin gene by inactivating tissue-specific DNA-binding protein in rat liver. *Biochemical Journal* **309**, 242–248.
- Oka T, Komori N, Kuwahata M, Sassa T, Suzuki I, Okada M & Natori Y (1993) Vitamin B₆ deficiency causes activation of RNA polymerase and general enhancement of gene expression in rat liver. *FEBS Letters* **331**, 162–164.
- Oka T, Komori N, Kuwahata M, Suzuki I, Okada M & Natori Y (1994) Effect of vitamin B₆ deficiency on the expression of glycogen phosphorylase mRNA in rat liver and skeletal muscle. *Experientia* **50**, 127–129.
- Oka T, Kuwahata M, Sugitatsu H, Tsuge H, Asagi K, Kohri H, Horiuchi S & Natori Y (1997) Modulation of albumin gene expression by amino acid supply in rat liver is mediated through intracellular concentration of pyridoxal 5'-phosphate. *Journal of Nutritional Biochemistry* **8**, 211–216.
- Potera C, Rose DP & Brown RR (1977) Vitamin B₆ deficiency in cancer patients. *American Journal of Clinical Nutrition* **30**, 1677–1679.
- Tryfiates GP (1980) *Vitamin B₆: Metabolism and Role in Growth*. Westport, CT: Food and Nutrition Press.
- Tully DB, Allgood VE & Cidlowski JA (1994) Modulation of steroid receptor-mediated gene expression by vitamin B6. *FASEB Journal* **8**, 343–349.
- Venegas A, Martial J & Valenzuela P (1973) Active site-directed inhibition of E. coli DNA-dependent RNA polymerase by pyridoxal 5'-phosphate. *Biochemical and Biophysical Research Communications* **55**, 1053–1059.
- Verstraete M & Zoldhelyi P (1995) Novel antithrombotic drugs in development. *Drugs* **49**, 856–884.

Proceedings of The Nutrition Society

Editor:
G Goldberg
London, UK

**To order your subscrip-
tion or for
more information con-
tact:**

CABI Publishing,
CAB International,
Wallingford,
Oxon, OX10 8DE, UK
Tel: +44 (0)1491 832111
Fax: +44 (0)1491 829292
Email: publishing@cabi.org

CABI Publishing,
CAB International,
10 East 40th Street,
Suite 3203,
New York, NY 10016,
USA
Tel: 212 481 7018
Toll free: 800 528 4841
Fax: 212 686 7993
Email: cabi-nao@cabi.org



Publishes the Proceedings of
The Nutrition Society on behalf of
The Nutrition Society

Available on the Internet at
www.cabi-publishing.org/journals

Throughout the year, The Nutrition Society holds important meetings and symposia, often in collaboration with other learned societies, where international experts are invited to speak on topics of particular interest in nutritional science.

The 2002 volume will feature papers and abstracts presented at Nutrition Society Symposia including:

- Nutritional effects of new processing technologies
- Overweight and obesity, a growing concern
- Nutritional adaptation to pregnancy and lactation
- Nutritional aspects of food safety
- 2001 A nutritional odyssey – Beyond the balanced diet
- Manipulating early diet
- Micronutrient supplementation, is there a case?
- Achieving a balanced diet in the developing world: strategies to meet micronutrient needs
- Evolving attitudes to food and nutrition
- Dietary fat – how low should we go?
- Endocrine and nutritional manipulation of the metabolic response to stress
- Nutrition for life

All this key information can be at your fingertips during 2002 by subscribing to the *Proceedings of The Nutrition Society*.

Six issues per year

ISSN: 0029-6651

2002, Volume 61

Print only	Internet only	Print/Internet Package
£295.00	£285.00	£310.00
\$495.00 Americas only	\$480.00 Americas only	\$520.00 Americas only
€ 470.00 EU only	€ 455.00 EU only	€ 495.00 EU only